The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
We are pleased to present below all posts archived in 'July, 2017'. If you still can't find what you are looking for, try using the search box.
For the full news article, please see http://www.bbc.co.uk/news/in-pictures-40582699
Read the rest of entry »
Hermes Investment Management (Hermes), the £30.8 billion manager, has agreed to sell a 50% equity stake in Milton Park to Canada Pension Plan Investment Board (CPPIB) for approximately £200 million.
Wickham Laboratories reports a successful completion of the MHRA audit process and the subsequent renewal of the GLP accreditation.
Isansys Lifecare Ltd is proud to announce it has been shortlisted for the Celebration of Innovation Awards 2017, a prestigious award celebrating the best of innovation in healthcare.
AMSBIO reports on an independent evaluation and use by I-Stem (Corbeil-Essonnes, France) of the Skeletal Muscle Differentiation kit - a cell culture media system to differentiate human stem cells into functional myotubes.
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.
PCI Pharma Services (PCI) has affirmed its position relative to the delayed enforcement of the US Food and Drug Administration (FDA)’s Compliance Policy for ‘Product Identified Requirements Under the Drug Supply Chain Security Act' (DSCSA).
Ipsen has cut the price of its kidney cancer Cabometyx to help secure its place within the NHS’ routine commissioning stream, helping to over-turn a previous decision that it did not represent value for money.
Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
Eli Lilly has welcomed a decision by the UK Supreme Court that alternative salt forms of its cancer drug Alimta.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. firstname.lastname@example.org.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.